TY - JOUR
T1 - Essential human resources for antimicrobial stewardship teams in Japan
T2 - Estimates from a nationwide survey conducted by the Japanese Society of Chemotherapy
AU - Maeda, Masayuki
AU - Muraki, Yuichi
AU - Kosaka, Tadashi
AU - Yamada, Takehiro
AU - Aoki, Yosuke
AU - Kaku, Mitsuo
AU - Seki, Masafumi
AU - Tanabe, Yoshinari
AU - Fujita, Naohisa
AU - Niki, Yoshihito
AU - Morita, Kunihiko
AU - Yanagihara, Katsunori
AU - Yoshida, Koichiro
AU - Kawaguchi, Tatsuya
N1 - Funding Information:
This work was supported by the Japanese Society of Chemotherapy.
Funding Information:
Masafumi Seki received speaker honoraria from Astellas Pharma, Inc., Dainippon Sumitomo Pharma Co., Ltd., Daiichi Sankyou Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Meiji Seika Pharma Co., Ltd., MSD Japan, Pfizer Japan, Inc., research grants from Astellas Pharma, Inc., Nippon Boehringer Ingelheim Co., Ltd., Daiichi Sankyou Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Meiji Seika Pharma Co., Ltd., MSD K.K., Shionogi & Co., Ltd.
Funding Information:
Katsunori Yanagihara received speaker honoraria from Pfizer Japan, Inc., Daiichi Sankyo Co., Ltd., Astellas Pharma, Inc., Taisho Toyama Pharmaceutical Co., Ltd., Asahi Kasei Pharma Co., Ltd., and BD Japan, research fees from Taisho Toyama Pharmaceutical Co., Ltd., Meiji Seika Pharma Co., Ltd., Kyorin Pharmaceutical Co., Ltd., and Roche Diagnostics K.K., and research grants from Dainippon Sumitomo Pharma Co., Ltd., MSD K.K., Daiichi Sankyo Co., Ltd., Astellas Pharma, Inc., Pfizer Japan, Inc., Taisho Toyama Pharmaceutical Co., Ltd., and Biofermin Seiyaku Co., Ltd.,
Funding Information:
Yoshihito Niki received speaker honoraria from Pfizer Japan Inc., Astellas Pharma Inc., Taisho Toyama Pharmaceutical Co., Ltd., MSD K.K., Dainippon Sumitomo Pharma Co., Ltd., Asahikasei Pharma Corporation, Meiji Seika Pharma Co., Ltd., Daiichi Sankyou Co., Ltd. and research grants from Daiichi Sankyou Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., MSD K.K., Astellas Pharma Inc., Shionogi & Co., Ltd. Yoshihito Niki is endowed chairs and funded by Shionogi & Co., Ltd., Meiji Seika Pharma Co., Ltd., Fujifilm Co., Ltd., Daiichi Sankyo Co., Ltd., Astellas Pharma Inc., Kyorin Pharmaceutical Co., Ltd., and Toyama Chemical Co., Ltd.
PY - 2019/9
Y1 - 2019/9
N2 - Implementation of antimicrobial stewardship programs (ASPs) with multidisciplinary antimicrobial stewardship teams (ASTs) is critical for appropriate antimicrobial use at healthcare facilities. Although the Japanese medical reimbursement system was revised to allow fees for ASP implementation, several concerns remain, including understaffing and enforcement of the recommendations on ASTs and ASPs in practice. Furthermore, there are no recommendations on full-time equivalents (FTEs) of the core members in ASTs in Japan. This committee report presents our recommendations on ASTs based on an analysis of the nationwide survey on implemented ASPs and staff FTEs at 1358 healthcare facilities conducted by the Japanese Society of Chemotherapy. Our report provides a directive for structural and financial support of ASTs and should aid in planning for the enhancement of AST practices and the organization of new ASTs.
AB - Implementation of antimicrobial stewardship programs (ASPs) with multidisciplinary antimicrobial stewardship teams (ASTs) is critical for appropriate antimicrobial use at healthcare facilities. Although the Japanese medical reimbursement system was revised to allow fees for ASP implementation, several concerns remain, including understaffing and enforcement of the recommendations on ASTs and ASPs in practice. Furthermore, there are no recommendations on full-time equivalents (FTEs) of the core members in ASTs in Japan. This committee report presents our recommendations on ASTs based on an analysis of the nationwide survey on implemented ASPs and staff FTEs at 1358 healthcare facilities conducted by the Japanese Society of Chemotherapy. Our report provides a directive for structural and financial support of ASTs and should aid in planning for the enhancement of AST practices and the organization of new ASTs.
KW - Antimicrobial stewardship
KW - Full-time equivalent
KW - Human resource
KW - Medical fee
UR - http://www.scopus.com/inward/record.url?scp=85066849532&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85066849532&partnerID=8YFLogxK
U2 - 10.1016/j.jiac.2019.05.012
DO - 10.1016/j.jiac.2019.05.012
M3 - Article
AN - SCOPUS:85066849532
VL - 25
SP - 653
EP - 656
JO - Journal of Infection and Chemotherapy
JF - Journal of Infection and Chemotherapy
SN - 1341-321X
IS - 9
ER -